Thus, we expected that the selective blockade of VIPR2 by KS-133, both alone and in combination with immune checkpoint inhibitors, such as anti-PD-1 antibodies would promote cancer-immune activation and induce anti-tumor effects. This evidence concerns the gene PDCD1 and neoplasm.